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This publication is the second in a series by the Expert Panel of the Flavor and Extract Manufacturers
Association summarizing the conclusions of its third systematic re-evaluation of the safety of ﬂavorings
previously considered to be generally recognized as safe (GRAS) under conditions of intended use. Re-
evaluation of GRAS status for ﬂavorings is based on updated considerations of exposure, structural
analogy, metabolism, pharmacokinetics and toxicology and includes a comprehensive review of the
scientiﬁc information on the ﬂavorings and structurally related substances. Of the 12 substituted thio-
phenes reviewed here, 11 were reafﬁrmed as GRAS based on their rapid absorption, metabolism and
excretion in humans and animals; the low estimated dietary exposure from ﬂavor use; the wide margins
of safety between the conservative estimates of intake and the no-observed-adverse effect levels; and
the lack of signiﬁcant genotoxic and mutagenic potential. For one of the substituted thiophenes, 3-acetyl-
2,5-dimethylthiophene, it was concluded that more detailed exposure information, comparative meta-
bolism studies and comprehensive toxicity data, including an in-depth evaluation of the mechanism of
action for any adverse effects observed, are required for continuation of its FEMA GRAS™ status. In the
absence of these data, the compound was removed from the FEMA GRAS list.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Following the adoption of the 1958 Food Additive Amendment
to the Food, Drug and Cosmetic Act (FDCA), the Flavor and Extract
Manufacturers Association (FEMA) established the “generally
recognized as safe” (GRAS) Program to evaluate the safety of food
ﬂavor ingredients based on scientiﬁc data. The safety of ﬂavor in-
gredients is determined by the FEMA Expert Panel, a body of in-
dependent scientists in ﬁelds of biochemistry, toxicology and
medicine who serve as reviewers of scientiﬁc data related to the
safety of ﬂavor ingredients (Smith et al., 2005a). The GRAS status of
ﬂavor ingredients is re-afﬁrmed periodically as part of ongoing
FEMA GRAS re-evaluations, a key component of the FEMA GRAS
Program. Re-evaluations are prioritized when there is a signiﬁcant
increase in exposure, or a substantial body of new scientiﬁc data
that has become available since the previous evaluation.
This paper is the second publication (following Marnett et al.,
2014) from the third cycle of re-evaluations of the GRAS status of
ﬂavoring substances. It represents the Expert Panel's re-evaluation
of the GRAS status of ﬂavoring substances that belong to the group
of substituted thiophenes, ﬁve-member aromatic heterocycles with
sulfur as the only heteroatom in the ring. The current re-evaluation
was initiated by the availability of new toxicity data, particularly
genotoxicity data for a number of substances in the group, and new
data on the metabolism of other representative substituted
thiophenes.2. Chemical identity
This group of twelve ﬂavoring agents (Table 1) includes thio-
phene derivatives, which are ﬁve-membered heterocycles con-
taining only sulfur as the ring heteroatom. The substances in this
group are all ring-substituted with one or more of the following
substituents or functional groups: aliphatic (3), thioether (1), di-
sulﬁde (1), alkyl thiol (2), alkyl alcohol (1) and alkyl ketone (4)
moieties (Table 1).
The structural class of the 12 thiophenes presented here was
determined based on the Decision Tree (DT) criteria (Cramer et al.,
1978), with 7 substances assigned to structural class II (FEMA Nos
3209, 4137, 4142, 4387, 4642, 4643, 4645) and 4 substances to class
III (FEMA Nos 3062, 3323, 4184, 4646). The compound 3-acetyl-2,5-
dimethylthiophene (previously FEMA No 3527) was assigned to
structural class II.
3. Status as ﬂavoring substances
Of the group of 12 substituted thiophene substances, four
members, 2-thienyl mercaptan, 5-methyl-2-
thiophenecarboxaldehyde, 2-thienyldisulﬁde and 3-acetyl-2,5-
dimethylthiophene were originally assigned their FEMA GRAS
status as part of the GRAS 3, 4, 5 and 11 publications, respectively
(Hall and Oser, 1965, 1970; Oser and Hall, 1972; Oser and Ford,
1978). Subsequently, these substances were re-evaluated by the
Expert Panel in 2001 and reafﬁrmed as GRAS under conditions of
use as ﬂavoring ingredients. The remaining eight members of this
S.M. Cohen et al. / Food and Chemical Toxicology 99 (2017) 40e5942group were determined to be GRAS under conditions of intended
use more recently (2005e2009) (Smith et al., 2005b, 2009;
Waddell et al., 2007).
All 12 substances in the group have also been evaluated by the
Joint FAO/WHOExpert Committee on Food Additives (JECFA) as part
of the group of sulfur heterocycles and structurally related ﬂavoring
ingredients, and the Committee concluded the substances would
not present a safety concern at the current levels of intake (JECFA,
2002, 2007, 2012). In addition, two of the substances in this group,
2-pentylthiophene and 2-hexylthiophene, were also evaluated by
EFSA in 2013 among a group of sulfur heterocycles for use as ﬂavor
ingredients under EFSA's regulatory jurisdiction. EFSA concluded
that additional toxicity data were required (these have become
available and are presented here) (EFSA, 2013a,b). In the same EFSA
evaluation, another four substances of this group, 2-thienyl
mercaptan, 5-methyl-2-thiophenecarboxaldehyde, 2-thienyl disul-
ﬁde and 3-acetyl-2,5-dimethylthiophene were included as sup-
porting substances (EFSA, 2013a). Two substances, 5-methyl-2-
thiophenecarboxaldehyde and 3-acetyl-2,5-dimethylthiophene,
were evaluated for genotoxicity by EFSA in 2013 (EFSA, 2013c-e). Of
these two, 5-methyl-2-thiophenecarboxaldehydewas concluded to
be safe for use as a ﬂavoring substance in food (EFSA, 2013c). Finally,
EFSAconcluded that one substance thatwas previouslyevaluatedby
JECFAwas safe for use as a ﬂavoring substance in a separate opinion
in 2013 (EFSA, 2013f).
4. Exposure
Thiophene derivatives are common components of food or are
structurally related to common components of food. They occur
naturally in a variety of foods including coffee, beef, pork, shrimp,
papaya and whiskey (Nijssen et al., 2015). Thiophenes are also
formed during cooking either via non-enzymatic browning re-
actions involving S-containing amino acids (e.g. cysteine) or alter-
natively, by the initial formation of hydrogen sulﬁde from the
sulfur-containing amino acids followed by reactions of hydrogen
sulﬁde with browning intermediates (Heath and Reineccius, 1986).
Annual volumes of production for these ingredients and the daily
per capita intake values calculated using the maximized survey-
derived intake (MSDI) method are summarized in Table 1. From the
most recent annual poundage surveys of 2005 and 2010, the annual
reportedvolumeof thiophenesusedasaddedﬂavoring ingredients to
food in the US has been minimal (the highest reported volume was
1 kg/year) (Gavin et al., 2008; Harman et al., 2013). Consequently, the
estimated daily per capita intake using the MSDI method has
remained very low (see Table 1). The annual production volume has
been reduced for at least two substances in the group, 2-
thienyldisulﬁde (from 0.5 to 0 kg/year) and 2-hexylthiophene (from
1to0.1kg/year). Four substances fromthisgroup [2-thienylmethanol,
2-acetyl-5-methylthiophene, 3,4-dimethylthiophene, and 1-(2-
thienyl)ethanethiol] were recently introduced as ﬂavoring in-
gredients (2009) and have only been included in the most recent
poundage survey (Harman et al., 2013). The most recent poundage
survey also includes one other GRAS substance, 2-pentylthiophene
that was not previously reported (Table 1).
The ﬂavor effect that the thiophenes impart explains the low
volume and use levels as added ﬂavor ingredients in food. Thio-
phenes often have a strong organoleptic proﬁle, such as burnt
caramel, roasted coffee, nutty, earthy, meaty, grassy, roasted onion,
as well as softer ﬂoral fruity effects, and are used as ﬂavor in-
gredients at average usual use levels of 0.001e2 ppm in a range of
food categories (Hall and Oser, 1965,1970; Oser and Hall, 1972; Oser
and Ford, 1978; Smith et al., 2005b, 2009; Waddell et al., 2007).
They aremost commonly used in baked goods, beverages, breakfast
cereals, candies, cheese, condiments, egg products, fats and oil, ﬁshproducts, frozen dairy products, gravies, instant coffee, meat
products, poultry, processed and reconstituted vegetables, soups,
snack foods, and gelatins and puddings (exceptional uses have
included up to 250 ppm in seasonings) (Smith et al., 2005b).
While seven of the thiophene derivatives in this ﬂavor group
have been detected in a broad range of foods, quantitative natural
occurrence data are available only for four substances, namely 5-
methyl-2-thiophenecarboxaldehyde, 2-thienylmethanol, 2-
pentylthiophene, and 2-acetyl-5-methylthiophene (Nijssen et al.,
2015). The estimated annual consumption of these ﬂavor in-
gredients from natural sources are 1426 kg, 7 kg, 2736 kg and
1165 kg, respectively (Table 1) (Stofberg and Grundschober, 1987).
The lack of additional quantitative data results in underestimation
of the exposure from sources where they occur naturally. Therefore,
consumption ratios can only partially be estimated and indicate
that exposure to the naturally occurring substances from ingestion
of traditional foods (even though data are only partially available) is
expected to be signiﬁcantly higher than the exposure from their use
as added food ﬂavors (i.e., consumption ratio substantially higher
than 1) (Table 1).
5. Absorption, distribution, metabolism and elimination
The metabolic fate of thiophenebased substances has been
studied in detail for a small number of substituted thiophene de-
rivatives that have been used as model structures to clarify differ-
ences in metabolic pathways based on speciﬁc structural features.
In addition, the metabolic pathways involved in the transformation
of thiophene derivatives were recently reviewed for a number of
xenobiotic compounds containing a thiophene substructure
(Gramec et al., 2014). The proposed metabolic pathways in that
comprehensive review are consistent with those presented here.
From these publications, it is noteworthy that the metabolic
transformation of thiophenes is a key element of their potential
biological activity and potential toxicity through the formation of
reactive intermediates (Gramec et al., 2014).
Common features of metabolism that have emerged in these
studies indicate that the majority of the 12 ﬂavoring ingredients are
expected to be subject to similar metabolic transformations. Based
on the body of evidence from published in vitro and in vivo meta-
bolic studies, substituted thiophenes are subject to biotransfor-
mation via oxidative reactions including, S-oxidation or ring
epoxidation/hydroxylation. These reactions are followed by
conjugation with glutathione (GSH) on the ring and subsequent
urinary elimination of mercapturic acids (these are described in
detail below and shown in Fig. 3). Structural features of the thio-
phene ring, including a) the presence and number of substitution
groups, b) the type of substitution groups, e.g., alkyl or acyl side
chains, and c) the location of substitution groups on the ring,
determine the relative contribution of the possible metabolic
pathways.
Speciﬁcally, alkyl-substituted thiophenes (related thiophene
ﬂavoring ingredients include FEMA numbers 4137, 4387, 4642, and
4646) including those with sulfur-containing side chains (related
FEMAnumbers include 3062, 3323, 4184, and 4645) are expected to
undergo primarily ring epoxidation and to a lower extent, S-
oxidation; alkyl side chains and sulfur-containing side chains have
less contribution to electron rearrangement following ring oxida-
tion relative to acyl side chains (related FEMA numbers 3209; 4142;
4643; and 3-acetyl-2,5-dimethylthiophene); 2-acyl substituted
thiophenes are expected to preferentially undergo ring epoxidation
(related FEMA numbers 3209; 4142; 4643); 3-acyl substituted
thiophenes are expected to preferentially undergo S-oxidation (3-
acetyl-2,5-dimethylthiophene) (Table 2). Relative to the other
thiophenes, 3-acetyl-2,5-dimethylthiophene contains unique
Table 1
Identity and exposure data for thiophenes and structurally related substances used as ﬂavoring ingredients.
Flavoring ingredient FEMA No. DT
Classa
CAS No. and Structure Most recent
annual
volumeb; kg
Daily per capita
Intakec
(“eaters only”)
Annual volume
in naturally
occurring foodsd; kg
Consumption
Ratioe
mg/d mg/kg bw/d
2-Thienyl mercaptan 3062 III 7774-74-5 0.1 0.01 0.0002 e NA
5-Methyl-2-
thiophenecarboxaldehyde
3209 II 13679-70-4
O
S
1 0.1 0.002 1426 1426
2-Thienyldisulﬁde 3323 III 6911-51-9
S
S
S
S
0.5 (2008) 0.06 0.001 e NA
2-Hexylthiophene 4137 II 18794-77-9 0.1 0.01 0.0002 þ NA
1-(3-Hydroxy-5-methyl-2-
thienyl)ethanone
4142 II 133860-42-1
OH
O
S
0 NA NA e NA
3-(Methylthio)-
methylthiophene
4184 III 61675-72-7
S
S
0 NA NA e NA
2-Pentylthiophene 4387 II 4861-58-9
S
0.1 0.01 0.0002 7 70
2-Thienylmethanol 4642 II 636-72-6 0 NA NA 2736 NA
2-Acetyl-5-methylthiophene 4643 II 13679-74-8 0 NA NA 1165 NA
3,4-Dimethylthiophene 4645 II 632-15-5 0 NA NA þ NA
1-(2-Thienyl)ethanethiol 4646 III 94089-02-8 0 NA NA e NA
3-Acetyl-2,5-
dimethylthiophene
No longer
GRAS
II 2530-10-1 0 0 0 þ NA
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a Cramer et al., 1978.
b FromHarman et al., 2013 for materials 3062e4387 and from interim industry survey for materials 4642e4646. Values greater than zero but less than 0.1 kg were reported
as 0.1 kg. The values are zero if reported as zero in current and/or previous surveys.
c MSDI (mg/person/day) calculated as follows: [[(annual volume, kg) x (1  109 mg/kg)]/[population x survey correction factor x 365 days]], where population (10%, “eaters
only”)¼ 31 106 for the USA, where the correction factor¼ 0.8, representing the assumption that only 80% of the annual ﬂavor volumewas reported in the poundage surveys
(Harman et al., 2013). [(mg/person/day)/body weight], where body weight ¼ 60 kg. Slight variations may occur from rounding.
d Quantitative data for the United States calculated using currently available natural occurrence concentrations, according to methods reported by Stofberg and
Grundschober (1987); “þ” indicates reported qualitative evidence of natural occurrence without quantitative data.
e The consumption ratio is calculated as follows: (annual consumption via food, kg)/(most recent reported volume as a ﬂavoring substance, kg).
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ﬂavoring ingredients. From the patterns that have emerged with
model thiophene structures, all the members of the thiophene
ﬂavoring ingredients group with the exception of 3-acetyl-2,5-
dimethylthiophene are expected to be metabolized to non-
reactive intermediates and/or be efﬁciently conjugated and
readily excreted.
Several cytochrome P450 (CYP) enzymes and related mono-
oxygenases (sensitive to metapyrone and diethylaminoethyl 2,2-
diphenylvalerate with EC50 of 10 mM, but distinct from ﬂavin mon-
ooxygenases and epoxide hydrolase) are involved in ring oxidation
reactions of model thiophenes (Dansette et al., 1990). In particular,
CYP1A1 (Dansette et al., 2005) and CYP2C9 (Rademacher et al.,
2012) are directly involved in oxidation of substituted thiophenes
and metabolic activation in vitro. Following oxidation reactions and
electron rearrangement, most metabolic intermediates of
substituted thiophenes are converted to stable hydrophilic products
that are anticipated to be efﬁciently conjugated and excreted. A key
factor in the efﬁcient deactivation of metabolic intermediates and
the formation of stable ﬁnal metabolic products and their elimina-
tion is the abundant availability of nucleophiles such as GSH.
Possible molecular mechanisms of thiophene oxidation and conju-
gationwithGSHhavebeenproposed (Valadon et al.,1996;Medower
et al., 2008; Dansette et al., 2009; Guengerich and Isin, 2014).
The thiophene structures shown in Fig. 1 provide insights into
the possible metabolic pathways of substituted thiophenes and are
used as models for the metabolic fate of the thiophene ﬂavoring
substances in this evaluation.5.1. Unsubstituted thiophene ring metabolism
Unsubstituted thiophene is biotransformed in vivo to mercap-
turic acid metabolites via S-oxidation reactions (Dansette et al.,
1992). In male Sprague-Dawley rats injected (i.p.) with 200 mg/
kg 3H-thiophene, approximately 31% of the radioactivity was
excreted in the urine within 15 h and an additional 4% within 50 h
(Dansette et al., 1992). The primary urinary metabolite, accounting
for more than 94% of the urinary radioactivity and 30% of the
administered dose, was the 2-mercapturic acid derivative of 2,5-
dihydrothiophene-S-oxide (dihydrothiophene sulfoxide mercap-
turate; DHTSM) (Fig. 2). These results indicate the formation of a
reactive S-oxide intermediate followed by a Michael-type addition
of GSH on position 2 of the thiophene ring, rather than an arene
epoxide intermediate, which would be consistent with the forma-
tion of 3-hydroxydihydrothiophene mercapturate (HDHTM)
(Fig. 2). The formation of other biotransformation products cannot
be excluded since this study did not account for the fate of the total
dose of parent compound administered. Previous evidence in-
dicates that approximately 32% of administered thiophene may be
exhaled unchanged (Bray et al., 1971).5.2. Substituted thiophenes metabolism
5.2.1. S-Oxidation
Substituted thiophenes undergo S-oxidation and aMichael-typeaddition of sulfur nucleophiles on ring position 2 of the activated
thiophene sulfoxide intermediate based on studies in vitro and
in vivo (Mansuy et al., 1991; Valadon et al., 1996). Benzothiophene
and [2,3-dichloro-4-(thiophene-3-carbonyl)phenoxy]acetic acid
(tienilic acid isomer, TAI) were incubated with activated liver
microsomal fractions in vitro in the presence of NADPH and mer-
captoethanol (100 mM) (Mansuy et al., 1991). The ﬁnal products, the
3-thioethanol conjugate of benzothiophene sulfoxide and the 2-
thioethanol conjugate of TAI sulfoxide, respectively, indicate the
formation of a S-oxide reactive intermediate for both structures
(Mansuy et al., 1991). The presence of an acyl substituent plays a
key role in the reactivity towards thiol nucleophiles, rendering the
S-oxide of TAI (bearing a keto substituent) more reactive than the S-
oxide of benzothiophene (lacking an acyl substituent) (Mansuy
et al., 1991).5.2.2. Ring epoxidation
In addition to the S-oxidation, substituted thiophenes are also
oxidized to an arene epoxide. Incubation of 2-phenylthiophene
with either rat liver microsomes or CYP1A1 in vitro in the pres-
ence of NADPH formed two reactive intermediates, an S-oxide and
an epoxide (Dansette et al., 2005). These intermediates in turn
resulted in four types of products, as identiﬁed by 1H NMR and MS
(Fig. 3): a) dimers of 2-phenylthiophene S-oxide (2PTSOD), repre-
senting Diels-Alder type adducts; b) GSH adducts of the S-oxide
metabolite, 2-phenylthiophene 2,5-dihydro-S-oxide (2PTGA),
formed by 1,4-Michael-type addition of GSH to the ring; c) GSH
adducts resulting from a nucleophilic attack of GSH on an inter-
mediary metabolite that was predicted to be the 4,5-epoxide of 2-
phenylthiophene (2PTGB); and d) 2-phenylthiolene thiolactone
(2PTT), a rather unstable metabolite (Dansette et al., 2005). 2PTSOD
and 2PTGA formation result from the S-oxide intermediate, 2PTGB
forms from the epoxide intermediate and the 2PTT can be formed
by oxygen isomerization in either pathway (Fig. 3).
Studies with thiophene pro-drugs, such as clopidogrel (Plavix®;
(þ)-(S)-methyl 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyr-
idin-5(4H)-yl)acetate) andprasugrel (Efﬁent®; (RS)-5-[2-cyclopropyl-
1-(2-ﬂuorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyr-
idin-2-yl acetate) have shown that the thiolactones formed after an
initial oxidation of the thiophene ring (at position 2) are further
oxidized resulting in ring opening and sulfenic acid isomeric metab-
olites (based on the position of the remaining double bond) (Dansette
et al., 2009, 2010; Mansuy and Dansette, 2011). The ﬁrst oxidation
reaction is catalyzed by CYP 1A2, 2B6 and 2C19. The second oxidation
and ring opening can be catalyzed by CYP 3A4, 2C9, 2B6 and 2C19 in
the presence of NADPH leading to one isomer of sulfenic acid (a,b
unsaturated; active metabolite), or by paraoxonase 1 (PON1) leading
to the other isomer (inactive metabolite) of sulfenic acid (Dansette
et al., 2009, 2012a,b; Gramec et al., 2014). Similar to PTT (Fig. 3), the
thiolactones of these pro-drugs are formed by either S-oxidation or
ring epoxidation (Dansette et al., 2009; Shimizu et al., 2009; Gramec
et al., 2014).5.2.3. The position of the acyl-substitution group: 2- and 3- isomers
The position of substitution on the thiophene ring plays a key
Table 2
Structural features of thiophene ﬂavoring ingredients relevant to their metabolic fate.
2-Substitution 3-Substitution
Alkyl- Acyl- Alkyl- Acyl-
3062a 3209
4184
3-acetyl-2,5-dimethylthiophene
3323
4142
4645
4137
4643
4387
4642
4646
a GRAS numbers.
Fig. 1. Substituted model thiophene structures tested in metabolic studies.
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toward cell components and downstream effects. Tienilic acid
([2,3-dichloro-4-(thiophene-2-carbonyl)phenoxy]acetic acid; TA)
(a diuretic drug) and its regioisomer (TAI) differ only in the position
of the aroyl substitution group (position 2 and 3, respectively)
(Fig. 1). When these isomeric thiophenes were incubated in vitro
with phenobarbital-treated rat liver microsomal fractions in the
presence of NADPH and O2, they resulted in different ratios of
reactive metabolites (Dansette et al., 1990). Ring oxidation of 14C-
labelled TA was the predominant metabolic pathway, resulting
primarily in formation of a 5-OH metabolite (65%), followed by a
substantial fraction (30%) of other metabolic intermediates irre-
versibly bound onto microsomal proteins (described as “reactive
fraction”) and a relatively minor fraction (3%) of other polar me-
tabolites (Dansette et al., 1990). In contrast, the 3-regioisomer, TAI,
resulted predominantly in “reactive fraction” (80%) and lower yield
of ring-hydroxylated product (18%) in the same system (Dansette
et al., 1990). The reactivity of the intermediates of the 3-
regioisomer was approximately 5-fold higher (covalent binding of
12 nmol/nmol CYP/20min) than that of the 2-keto isomer
(2.5 nmol/nmol CYP/20min). The “reactive fraction” results from a
metabolic pathway other than ring oxidation, as described below.
While ring oxidation leading to the 5-OH product is the main
metabolic pathway for TA (Dansette et al., 1990), TAI is subject to S-
oxidation (Mansuy et al., 1991; Valadon et al., 1996; Rademacher
et al., 2012) as well as ring oxidation (Rademacher et al., 2012)
(Fig. 4A and B). Oxidation of TAI by recombinant CYP 2C9 in the
presence of NADPH, results in two products, an S-oxide dimer and a
pair of hydroxythiophene/thiolactone tautomers (Fig. 4 B), from theS-oxide and arene epoxide intermediates, respectively
(Rademacher et al., 2012). According to in silicomodelling, 5-OH-TA
and 5-OH-TAI (subsequently rearranged to their thiolactone iso-
mers) result from an arene epoxide intermediate rather than from
an S-oxide with subsequent 1e5 oxygen migration (Rademacher
et al., 2012). Although TA S-oxide intermediate and its products
were not detected by Rademacher and others, this study used
Supersomes™ engineered to express CYP 2C9 and may
Fig. 2. Known metabolites of thiophene oxidation via sulfoxide and epoxide in-
termediates (Dansette et al., 1992). DHTSM: dihydrothiophene sulfoxide mercapturate;
HDHTM: 3-hydroxy dihydrothiophene mercapturate.
Fig. 3. Metabolism of 2-phenylthiophene (adapted from Dansette et al., 2005).
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shown to catalyze the S-oxidation of 2-phenylthiophene (Dansette
et al., 2005).5.3. Conjugation with sulfur nucleophiles
Sulfur nucleophiles are critical in quenching the reactive in-
termediates of substituted thiophenes, thusmitigating potential for
toxicity from the intermediate. The fraction of stable water soluble
metabolites relative to reactive metabolites bound on microsomal
proteins increases in the presence of mercaptoethanol, N-ace-
tylcysteine or GSH in vitro (Dansette et al., 1990; Valadon et al.,
1996). Empirically, the presence of GSH or other sulfur nucleo-
philes favored the formation of themore stable 5-OHmetabolite for
both TA and TAI, relative to the reactive metabolites involved in
microsomal binding, which were reduced up to 10-fold (Dansette
et al., 1990). This shift in reactivity presumably results from the
sequestration of S-oxide derived reactive intermediates by GSH as
shown in Fig. 5. The available concentration of sulfur nucleophiles
is directly related to the degree of quenching of the reactive in-
termediates resulting from incubation of TAI with rat livermicrosomes in vitro: in the absence of a sulfur nucleophile, 57%
soluble metabolites and 21% microsome-bound metabolites were
detected; in the presence of 100 mM mercaptoethanol or N-ace-
tylcysteine, the fraction of soluble metabolites increased to
approximately 93% of parent compound (>60% consisted of the two
diastereomers of the 2-mercapturate of TAI S-sulfoxide) and the
microsome-bound species decreased to a mere 5%; with increasing
concentrations (1e2 mM) of nucleophile, further metabolic trans-
formations occur, including additional covalent binding of mer-
captoethanol on position 4 of the ring and on the ring S, followed by
ring opening (~57%), ring closure and almost exclusive formation of
4-mercaptoethanol conjugate of 4,5-dihydro-TAI as the ﬁnal stable
metabolite (Fig. 5). Nucleophile conjugation of activated thiophene
intermediates has also been conﬁrmed in vivo (see section below).5.3.1. Factors determining conjugation efﬁciency
Both the type of CYP isoforms and the presence or absence of
GSH determines the relative yield of reactive intermediates and the
ﬁnal metabolic products. As expected, the GSH conjugates of 2-
phenylthiophene (2PTGA and 2PTGB; Fig. 3) are formed at higher
proportions (20% and 30%, respectively) in the presence of GSH
following activation by liver microsomes at the expense of both
2PTSOD and PTT (reduced from 35% to 12% and from 30% to 3%,
respectively) (Dansette et al., 2005). The S-oxide dimer of 2-
phenylthiophene is the primary product (31%) of recombinant
CYP 1A1 in the presence of GSH, followed by PTT and the GSH
conjugates A and B (4%, 6% and 3%, respectively). This metabolite
proﬁle indicates that CYP 1A1 is not involved in the formation of an
arene epoxide and that other CYP enzymes present in microsomal
preparations are involved in the formation of both S-oxide and
epoxide pathways (Dansette et al., 2005). At least one other CYP
enzyme involved is the CYP 2C9 (Rademacher et al., 2012). This
enzyme oxidizes both the 2- and 3-aroyl thiophene isomers and
catalyzes both the S-oxidation and arene oxidation pathways
(Rademacher et al., 2012).
The location of GSH conjugation of activated thiophene
Fig. 4. Possible metabolic pathways for the biotransformation of 2-acylthiophene (A) compared to 3-acylthiophene (B), based on documented empirical evidence and in silico
modelling (Dansette et al., 2005, Valadon et al., 1996; Rademacher et al., 2012).
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(S-oxidation or ring oxidation) and on the presence of other sub-
stituents. For example, GSH binding following S-oxidation occurs
via Michael-type reaction on a carbon adjacent to the ring sulfur
(ring positions 2, 5) (Dansette et al., 1992, 2005; Valadon et al.,
1996). Binding of GSH on the ring occurs at position 3 following
ring epoxidation (Dansette et al., 1992; 2005). In 2-substituted
thiophenes such as 2-phenylthiophene (2 PT) (Dansette et al.,
2005) or 2-acetylthiophene (Yan et al., 2005), GSH binding occurs
at the ring position not bearing the substituent (position 5).5.4. In vivo metabolism
The metabolic fate of thiophenes in vivo is consistent with the
pathways described above, based on the nature of urinary metab-
olites detected following oral administration in Sprague-Dawley
rats (Valadon et al., 1996). Nucleophilic conjugation of activated
thiophene intermediates is also conﬁrmed in vivo (Valadon et al.,
1996). GSH, present at high concentrations in hepatocytes
(1e5 mM), is the main sulfur nucleophile in vivo resulting information of mercapturate conjugates similar to those seen in vitro
with mercaptoethanol. Injection (i.p.) of male Sprague-Dawley rats
with 30mg/kg bw of 14C-labelled TAI (at the keto position), resulted
in a mixture of two diastereomers of the 4-mercapturate conjugate
of 4,5-dihydro-TAI (Valadon et al., 1996). However, unlike the yields
of mercapturate conjugates seen in vitro, recovery of metabolites in
the urine does not fully account for the administered dose. Only
20% of the administered dose of radiolabelled TAI was accounted
for in the urine within 24 h and the urinary mercapturate conju-
gates accounted for only 2% of the administered radioactivity and
together for approximately 15% of all urinary radioactivity. Rela-
tively higher fractions of mercapturate conjugates (40% and 30%)
were reported in other studies (Bray et al., 1971; Dansette et al.,
1992) in male Sprague-Dawley rats. In a limited study, urinary
mercapturate conjugates in rats were reported for non-substituted
thiophene and its 2-bromo- and 3-bromo-derivatives (3%, 6% and
14%, respectively) (Hickman et al., 1992). Formation of thiophene
sulfoxide was not reported in this study for the bromo-thiophene
derivatives (Hickman et al., 1992). The reasons for the low re-
coveries of mercapturate and other urinary metabolites in these
Fig. 5. Nucleophile conjugates of TAI sulfoxides detected in vitro in the presence of liver microsomes, NADPH and mercaptoethanol, at increasing concentrations of nucleophile. The
2-mercapto-TAI results only under acidic conditions (Valadon et al., 1996).
S.M. Cohen et al. / Food and Chemical Toxicology 99 (2017) 40e5948studies are unclear and it should be noted that no other tissues
were examined that might have clariﬁed the alternate fate of the
administered thiophene compounds.
In humans, metabolism of thiophene pro-drugs, such as clopi-
dogrel and ticlopidine results in the formation of a thiolactone (e.g.
2-oxo-clopidogrel) followed by oxidation of the ring to the sulfenic
acid that is subsequently conjugated with GSH (Gramec et al., 2014;
Farid et al., 2010). In prasugrel, the thiolactone is formed via
isomerization of the 2-hydroxyl group that results from ester hy-
drolysis and it also proceeds to sulfenic acid metabolites (Farid
et al., 2010). Oxidation of the parent compounds to the thio-
lactones is mediated via CYP 1A2, 2B6 and 2C19, whereas the sec-
ond oxidation step is mediated via CYP 3A4, 2C9, 2B6 and 2C19
(Kazui et al., 2010). Urinary excretion of ticlopidine and prasugrel
accounts for 60% and 68%, respectively, of the administered dose of
these substances. The major urinary metabolite of prasugrel (21% of
administered dose) is derived from a hydroxylated thiophene in-
termediate while other products are derived from other hydrolysis
metabolites (Farid et al., 2010). Approximately 20e27% of the
administered dose is recovered in the feces either from biliary
excretion or as non-absorbed compound (Farid et al., 2010).1 Density ¼ 1.086 g/mL; for rats weighing 200-250 g.5.5. Summary of metabolism
From the studies described above, the key structural features
that determine the metabolic fate of model substituted thiophene
compounds were characterized, including a) the presence and
number of substitution groups, b) the type of substituents, e.g. alkyl
or acyl side chains, and c) their location on the ring (Rademacher
et al., 2012; Gramec et al., 2014). Generally, a) metabolites
derived from S-oxide intermediates are more reactive than those of
the arene oxide intermediates (Dansette et al., 1990), b) metabolites
of S-oxides of acyl-substituted thiophenes are more reactive than
the equivalent of thiophenes lacking the acyl substituent (Mansuy
et al., 1991) and c) 3-acyl substituted thiophenes favor S-oxide in-
termediates more than 2-acyl isomers (Dansette et al., 1990;
Rademacher et al., 2012).6. Toxicology
6.1. Acute toxicity
A limited number of studies have assessed the acute oral toxicity
of thiophenes and indicate a low toxic potential. In a GLP oral acute
toxicity study in Sprague-Dawley rats, 3-acetyl-2,5-
dimethylthiophene had an LD50 of 455 mg/kg bw/day in males
and 594 mg/kg bw/day in females (combined LD50 of 510 mg/
kg bw/day for male and female) (Mallory, 1982). 2-Thienyldisulﬁde
had an oral LD50 value of 400 mg/kg bw in male and female mice
(Table 3) (Moran and Easterday, 1980). The structurally related
thiophene-2-carboxaldehyde had an oral LD50 of 565 mg/kg bw in
mice and 915 mg/kg bw in rats (Sharp, 1979). The unsubstituted
thiophene has reported LD50 values of 1902 and > 500 mg/kg bw in
mice (O'Donoghue, 1979; Eli Lilly Co, 1992) and 1131 and 3120 mg/
kg bw in rats (O'Donoghue, 1979; Younger, 1965). An acute neuro-
toxicity and behavioral toxicity study was conducted in Wistar-
Kyoto rats with unsubstituted thiophene, based on earlier studies
indicating that thiophene induced degeneration of granule cells
selectively in the cerebellum in rats. Treatment with daily intra-
muscular injections of 0.15 mL thiophene (equivalent to
651e814 mg/kg bw/day)1 for 3 days resulted in ataxia and con-
vulsions in all animals within 24 h (Mori et al., 2000).6.2. Short-term toxicity studies
6.2.1. 5-Methyl-2-thiophenecarboxaldehyde and 3-acetyl-2,5-
dimethylthiophene
5-Methyl-2-thiophenecarboxaldehyde (FEMA No. 3209) and 3-
acetyl-2,5-dimethylthiophene were tested in male and female
Fischer 344 rats (5/sex/group) for 14 days, each at a single dietary
concentration estimated to give an average daily intake of 10mg/kg
bw (Gill and Van Miller, 1987). Neither substance caused any
notable or biologically relevant toxicity. No treatment-related
Table 3
Acute oral toxicity studies for thiophene derivatives used as ﬂavoring ingredients.
Flavoring ingredient Species, Sexa LD50
(mg/kg bw)
Reference
2-Thienyldisulﬁde Mouse; M,F 400 Moran and
Easterday 1980
3-Acetyl-2,5-
dimethylthiophene
Rat; M,F 455 (M)
594 (F)
Mallory 1982
a M ¼ Male; F¼Female; NR¼Not Reported.
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aminations compared to control (Gill and Van Miller, 1987).
6.2.2. 5-Ethylthiophene-2-carboxaldehyde
This compound is not a ﬂavoring ingredient but it is structurally
directly related to the ﬂavoring 5-methyl-2-thiophenecarbox-
aldehyde (FEMA No 3209). In a 14-day dietary study, male and fe-
male Hsd:SD® rats (3/sex/group) were fed a diet containing 0, 240,
2400 and 12,000 ppm of 5-ethylthiophene-2-carboxaldehyde,
estimated to correspond to 22,194 and 676mg/kg bw/day for males
and 22, 195 and 686 mg/kg bw/day for females (Bauter, 2012). No
mortality was observed throughout the course of the study. Clinical
signs in both males and females included reductions in fecal vol-
ume, body weight gain, body weight (up to 21%), food consumption
and food efﬁciency, that were statistically signiﬁcant at 12,000 ppm
for all males but not females. Themales in the 2400 ppm group also
showed a small reduction in body weight in the ﬁrst 3 days (2.2%).
Other observations in males of the high dose group included red
oral/nasal discharge, red facial and anogenital staining, nose/snout
swelling, cuts and eschar, tremors, biting and hyperactivity. This
study provided an upper tolerated intake level of 240 ppm for male
rats and 2400 ppm for females (equivalent to 22 and 195mg/kg bw/
day, respectively) for the follow-up study of longer duration
(described below) (Bauter, 2012).
6.3. Subchronic toxicity studies
The results of subchronic toxicity studies are summarized in
Table 4.
6.3.1. 5-Ethylthiophene-2-carboxaldehyde
As stated above, this compound is not a FEMA GRAS ﬂavoring
ingredient but it is used in other global regions as a ﬂavoring
substance (EFSA, 2015), and is structurally related to the ﬂavoring
5-methyl-2-thiophenecarboxaldehyde (FEMA No 3209). It was
administered to male and female Sprague-Dawley® Crl:CD IGS rats
(10/sex/group), in an OECD compliant 90-day study, at doses of 0, 2,
7.5 and 75 mg/kg bw/day by gavage (Bauter, 2013a). Since the liverTable 4
Subchronic toxicity studies for thiophene derivatives used as ﬂavoring ingredients.
Flavoring ingredient Species,
Sexa
No. Test groups/Group
sizeb
Route
2-Thienyldisulﬁde Rats; M,F 1/30 Dietary
2-Pentylthiophene Rats; M,F 3/10 Gavage
2-Pentylthiophene Rats; M,F 1/10 Gavage
2-Pentylthiophene Rats; M,F 3/20 Dietary
5-Ethylthiophene-2-
carboxaldehydee
Rats; M.F 3/20 Gavage
a M ¼ Male; F¼Female.
b Total number of test groups does not include control animals. Total number per test
c Assuming intake as high as the combined intake of the group (Sum of MSDI ¼ 0.003
d The study was performed at a single dose level and produced no adverse effects. Th
e NOAEL of structural analogue applies to the ﬂavoring substance 5-methyl-2-thiophewas a target organ, complete histopathological examinations of
liver tissue were conducted and other tissues were preserved for
future histopathological examination.
There were no unscheduled deaths in the test groups. There
were no remarkable ﬁndings in ophthalmic examinations, urine
analysis, clinical pathology, macroscopic, microscopic, or organ
weight changes and no other changes in hematology, coagulation
or serum chemistry parameters that were considered biologically
relevant. Upon microscopic examination, high-dose males and fe-
males showed atrophy of the submandibular salivary gland but
there were no comparable ﬁndings at the two lower doses. Based
on this 90-day oral toxicity study in rats, the no-observed-adverse-
effect level (NOAEL) for 5-ethylthiophene-2-carboxaldehyde
administered via gavage was 7.5 mg/kg bw/day for males and fe-
males (Bauter, 2013a). Based on structural similarity, the Panel
considered this NOAEL appropriate for 5-methyl-2-thio-
phenecarboxaldehyde (ﬂavoring ingredient). Compared to the
estimated human exposure of the ﬂavoring ingredient (MSDI;
0.002 mg/kg bw/day), this NOAEL results in a margin of safety of
3,750,000 (Table 4).
6.3.2. 2-Thienyldisulﬁde
A 90-day dietary study for 2-thienyldisulﬁde (FEMA No 3323)
was conducted in weanling rats (15/sex/group strain not reported)
at a single target intake level of 0.29 mg/kg bw/day (Morgareidge
and Oser, 1970). This level was designed to be 100 times higher
than the estimated Possible Average Daily Intake (PADI) from its use
as a ﬂavoring substance at the time of the study. The PADI method
(Morgareidge and Oser, 1970) assumes that all foods in a food
category always contain that substance and that the food category
is consumed daily (Oser and Hall, 1977), and therefore, it is a very
conservative overestimate of the average human daily intake for
low volume ﬂavoring substances (Hall and Ford, 1999).
Neither overt signs of toxicity normortality were noted between
2-thienyldisulﬁde treated and control animals. There were no dif-
ferences in bodyweights and food consumption, hematology, blood
chemistry and urine analysis, absolute or relative liver and kidney
weights and no evidence of gross pathology or histopathology of
major organs. The dose of 0.29 mg/kg bw/day, the only dose tested,
would result in a NOAEL giving a margin of safety of 290,000
compared to the estimated human dietary exposure (MSDI,
0.001 mg/kg bw/day) to this substance from its intended use as a
ﬂavoring ingredient (Table 4).
6.3.3. 2-Pentylthiophene
2-Pentylthiopene (FEMA No 4387) was administered to
Sprague-Dawley Crl:CD® (SD) IGS BR rats (5/sex/group) at dose
levels of 0, 15, 150 or 500 mg/kg bw/day by gavage, in a 28-dayDuration
(days)
NOAEL (mg/kg bw/
d)
Margin of
Safetyc
Reference
90 0.29d 290,000 Morgareidge and Oser
1970
28 15 75,000,000 Dhinsa et al., 2006
28 3.0d 15,000,000 Marr and Watson, 2007
90 33 165,000,000 Bauter, 2013b
90 7.5 3,750,000 Bauter, 2013a
group includes both male and female animals.
mg/kg bw/day).
e NOAEL is probably higher than the dose level reported here.
necarboxaldehyde.
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highest dose (500 mg/kg bw/day) and most animals in the middle
dose. Minor non-adverse effects were seen in only twomales at the
lowest dose.
More speciﬁcally, adverse effects observed in both males and
females at the middle and high doses (150 and 500 mg/kg bw/day)
included hemolytic anemia, increases in bilirubin and alanine
aminotransferase, increases in absolute and relative liver, kidney
and spleen weights, centrilobular hepatocyte hypertrophy and
globular accumulations of eosinophilic material in the renal tu-
bules. Splenic toxicity included increased incidence of higher
grades of severity of extramedullary hematopoiesis, hemosiderin
accumulation and associated hyperemia. The centrilobular hepa-
tocyte hypertrophy is likely related to constitutive androstane re-
ceptor (CAR) and/or pregnane X receptor (PXR) activation, and
consequently, CYP induction (Williams and Iatropoulos, 2002;
Graham and Lake, 2008; Thoolen et al., 2010; Hall et al., 2012).
Hypertrophy of follicle-lining cells of the thyroid gland in males
was observed only at 150mg/kg bw/day and it was postulated to be
secondary to activation of CAR/PXR in the liver, leading to increased
metabolism of circulating thyroid hormones and compensatory
increased thyroid stimulating hormone. This mechanism is
considered unique to rodents and thus not relevant to humans
(Graham and Lake, 2008). At the highest dose (500 mg/kg bw/day),
hemosiderin pigment deposits in the liver and in the kidney tubular
epithelium, renal tubular hypertrophy and urinary bladder
epithelial hyperplasia with associated inﬂammatory features in
both tissues, were found.With the exception of increased salivation
in two animals and a slight increase in blood bilirubin, no
treatment-related adverse effects were detected at 15 mg/kg bw/
day, providing a NOAEL as reported by the authors of 15 mg/kg bw/
day (Dhinsa et al., 2006) that results in a margin of safety of
75,000,000 compared to the estimated exposure (MSDI, 0.0002 mg/
kg bw/day) to this ﬂavoring substance (Table 4).
The slight increase in blood bilirubin at the lowest dose (15 mg/
kg bw/day) was assessed in a follow-up 28-day study to evaluate
effects of 2-pentylthiophene in the spleen (Marr and Watson,
2007). The substance was administered at a single dose level of
3 mg/kg bw/day by gavage to Sprague-Dawley Crl:CD® (SD) IGS BR
rats (5/sex). No treatment-related changes were noted in clinical
pathology, body weight growth, hematology and blood chemistry,
nor were any signiﬁcant other toxicological effects in spleenweight
or macroscopic abnormalities (histopathological examination was
not conducted in this study). Based on this, a NOAEL of 3 mg/kg bw/
day, the only dose tested, could be established and results in a
margin of safety greater than 15,000,000 compared to the esti-
mated combined human exposure (MSDI, 0.0002 mg/kg bw/day) of
ﬂavor substances in this group (Table 4).
In a 90-day dietary study, CRL Sprague-Dawley CD®IGS rats (10/
sex/group) were fed a diet containing 0, 28, 140 and 700 ppm of 2-
pentylthiophene (Bauter, 2013b). The dose was determined to be
1.4, 7 and 33 mg/kg bw per day for males and 1.5, 8 and 39 mg/kg
bw per day for females, following stability analysis of the substance.
No further analysis to explain the reduction of stability in the diet
was performed. No mortality and no signiﬁcant clinical signs of
toxicity were observed among hematology, clinical chemistry,
coagulation and urine analysis parameters, or body weight
changes. Increased relative kidney weight seen in females of the
high dose group was the only macroscopic ﬁnding, and it was not
toxicologically signiﬁcant in the absence of associated speciﬁc gross
or microscopic ﬁndings. No microscopic observations were detec-
ted in the any of the tissues examined. In addition, there was no
increase in blood bilirubin at any dose level in this study. Therefore,
the NOAEL for 2-pentythiophene in the diet was determined to be
33 and 39 mg/kg bw/day for males and females, respectively(Bauter, 2013b) and results in a margin of safety of 165,000,000
compared to its estimated exposure (MSDI, 0.0002 mg/kg bw/day)
to this ﬂavoring substance (Table 4).
6.3.4. Thiophene
Unsubstituted thiophene is a substance that is approved for use
as a ﬂavor ingredient in Europe but does not have FEMA GRAS
status for the United States. In a 42-day repeat oral dosing study,
thiophene was administered to male and female Sprague-Dawley
rats (13/sex/group) via gavage, at doses of 0, 25, 100, or 400 mg/
kg bw/day (Nagao, 2006). Loss of balance was seen immediately
after administration of 100 or 400 mg/kg bw/day of thiophene.
Adverse effects were observed at 100 and 400 mg/kg bw/day
compared to control groups, including blood chemistry and organ
weights and histopathological changes in the liver, kidney, spleen
and cerebellum that increased in severity at the high dose. No
adverse effects were noted at the lowest dose level in this study,
which would indicate a NOAEL of 25 mg/kg bw/day (Nagao, 2006).
6.4. Developmental toxicity studies
6.4.1. Thiophene
Reproductive and developmental toxicity endpoints were eval-
uated as part of a short term toxicity study (Nagao, 2006). Sprague-
Dawley rats (13/sex/group)were administered0, 25,100, or 400mg/
kg bw/day of thiophene by gavage, for a 42-day period starting 14
days prior to cohabitation and extending through day 4 of lactation.
There were no adverse effects on any of the reproductive endpoints
evaluated, including copulation, ovulation, or fertility in any of the
treatment groups compared to control groups. Dams treated with
100 or 400 mg/kg bw/day of thiophene showed histopathological
changes in the cerebellum (pyknosis and necrosis of granular cells)
and abnormal lactation. No morphological abnormalities were
found in the offspring, with the exception of reduced birth weights
and decreased body weights and viability at postnatal day 4 in pups
born to dams treated with 400 mg/kg bw/day. The no-observed-
effect-level (NOEL) for reproductive toxicity was reported by the
authors to be 25 mg/kg bw/day for female rats and 400 mg/kg bw/
day for males (Nagao, 2006). The NOEL for developmental toxicity
reported by the authors was 100 mg/kg bw/day.
6.5. Chronic toxicity studies
No long-term toxicity studies or carcinogenicity studies were
found in the public literature for any of the eight ﬂavoring sub-
stances in this reevaluation, and no structural analogues were
found that have been tested in chronic rodent cancer bioassays.
6.6. Genotoxicity
In vitro and in vivo genotoxicity studies were recently conducted
for 5-methyl-2-thiophenecarboxaldehyde and 3-acetyl-2,5-
dimethylthiophene according to current OECD guidelines and GLP
standards. The results of these and other studies are summarized in
Tables 5 and 6 and are described below.
6.6.1. 5-Methyl-2-thiophenecarboxaldehyde
6.6.1.1. In vitro. The mutagenicity of 5-methyl-2-
thiophenecarboxaldehyde was tested according to OECD guide-
lines in Salmonella typhimurium strains TA98, TA100, TA1535,
TA1537 and TA102, both in the absence and in the presence of a
metabolic activation system (S-9) from livers of rats induced with
Aroclor 1254, in three experiments (Beevers, 2009). No dose-
related, reproducible or statistically signiﬁcant increases in rever-
tant numbers were observed in any of the test strains, at
Table 5
In vitro genotoxicity studies for thiophene derivatives used as ﬂavoring ingredients.
Substance Assay Test system Concentration Results Reference
5-Methyl-2-thiophenecarboxaldehyde Reverse mutation Salmonella
typhimurium
TA98, TA100
4-100 mmole/plate Negativea Lee et al., 1994
5-Methyl-2-thiophenecarboxaldehyde Reverse mutation S. typhimurium
TA98, TA1535, TA1537 and TA102
0.32e1000 mg/plateb Negativea Beevers 2009
5-Methyl-2-thiophenecarboxaldehyde Reverse mutation S. typhimurium TA98
TA100, TA102,
TA1535, and
TA1537
10.24e1000 mg/plateb, c, d
10.24e1000 mg/platee, f, g
25.6e2500 mg/plateb, c, h
4.096e400 mg/platee, f, i
Negativea Beevers 2009
5-Methyl-2-thiophenecarboxaldehyde Reverse mutation S. typhimurium
TA100, TA1535,
TA1537
156.25e5000 mg/plateb, f, j
156.25e5000 mg/plateb, c, k
Negativea Beevers 2009
5-Methyl-2-thiophenecarboxaldehyde Micronucleus Induction Human peripheral
blood lymphocytes
(Female and Male
Donors)
600-1000 mg/mlc, l
50-70 mg/mLf, l
120-350 mg/mLc, m
50-80 mg/mLf, l
Negativec
Weak Positivee
Lloyd 2011
3-Acetyl-2,5-dimethylthiophene Reverse mutation S. typhimurium TA98
TA100, TA102,
TA1535, and
TA1537
1.6e5000 mg/platea Negativea
Positivef, n
Lillford, 2009
3-Acetyl-2,5-dimethylthiophene Reverse mutation S. typhimurium TA98
TA100, TA102,
TA1535, and
TA1537
51.2e5000a, b Negativec
Positivef, n
Lillford, 2009
a In the absence and presence of metabolic activating system, S-9.
b Plate incorporation method.
c Without metabolic activation system, S-9.
d In strains TA98, TA102, TA1535 and TA1537.
e Pre-incubation method.
f With metabolic activation system, S-9.
g In strains TA98 and TA1535.
h In strains TA1535 and TA1537.
i In strains TA100, TA102 andTA1535.
j In strains TA100 and TA1535.
k In strains TA100, TA1535 and TA1537.
l 3 h incubation with 21 h recovery.
m 24 h incubation with no recovery.
n In strains TA98, TA100 and TA102.
Table 6
In vivo genotoxicity studies for thiophene derivatives used as ﬂavoring ingredients.
Substance Assay Test system Route of
Administration
Doses and test conditions Results Reference
5-Methyl-2-
Thiophenecarboxaldehyde
Micronucleus
Assay
Rat bone marrow Gavage 70, 350, and 700 mg/kg bw/day (males
only)
Negative Beevers,
2012
5-Methyl-2-
Thiophenecarboxaldehyde
Comet assay Rat
liver
Gavage 70, 350, and 700
mg/kg bw/day
(males only)
Negative Beevers,
2012
3-Acetyl-2,5-dimethylthiophene Micronucleus Assay Muta™Mice
(bone marrow)
Gavage,
28 days
125, 235, and 300 mg/kg bw/day
(males only)
Negative Beevers,
2013
3-Acetyl-2,5-dimethylthiophene Induction of lacZ-
mutations
Muta™Mice
(liver and
duodenum)
Gavage,
28 days
125, 235, and 300 mg/kg bw/day
(males only)
Negative
(duodenum)
Positive (liver)
Beevers,
2013
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(the maximum recommended concentration according to current
regulatory guidelines).
In an OECD-compliant in vitromicronucleus assay with cultured
human peripheral blood lymphocytes, 5-methyl-2-
thiophenecarboxaldehyde was tested for 3 h followed by 21 h re-
covery (3 þ 21 h) in the absence and presence of S-9 from livers of
rats induced with Aroclor 1254, or for 24 h without recovery
(24 þ 0 h) in the absence of S-9 (Lloyd, 2011). In the 3 þ 21 h in the
presence of S-9, cultures treated with 50, 60 and 70 mg/mL of 5-
methyl-2-thiophenecarboxaldehyde showed a weak positive
response, with only single replicate cultures exceeding the normal
historical control range. In the absence of S-9, no biologically
relevant increase in the MNBN frequencies were found in cellstreated for 3þ 21 h (600, 900 and 1000 mg/mL), or for 24þ 0 h (120,
240, 300, and 350 mg/mL). Despite the statistically signiﬁcant dif-
ferences, all mean MNBN frequencies of vehicle control and treated
cultures were within the normal range and the results were
considered equivocal.6.6.1.2. In vivo. The equivocal evidence of genotoxicity observed in
the in vitro micronucleus test was further examined in an OECD-
compliant in vivo study which included a Comet assay in the
liver, the primary site of metabolism, and themicronucleus assay in
the bone marrow in rats (Beevers, 2012). Han-Wistar male rats
(n ¼ 6/group) were treated with 5-methyl-2-
thiophenecarboxaldehyde by oral gavage for three consecutive
days and at doses of 70, 350 and 700 mg/kg bw/day (ethyl
S.M. Cohen et al. / Food and Chemical Toxicology 99 (2017) 40e5952methanesulfonate, 150 mg/kg bw/day was used as a positive con-
trol). The highest dose used was determined to be the maximum
tolerated dose (MTD) in a preliminary range ﬁnding study, where
mortality was observed at 1000 mg/kg bw/day. Treatment did not
cause any overt toxicity, with the exceptions of increased levels of
serum aspartate aminotransferase at 700 mg/kg bw/day and a
dose-dependent decrease in total cholesterol levels. Liver exposure
to the substance was indicated by histological observation of
glycogen deposits at 350 and 700 mg/kg bw/day along with
changes in liver enzymes. However, 5-methyl-2-
thiophenecarboxaldehyde did not induce DNA damage in the
liver; although mean Comet tail intensities and tail moments were
slightly higher in treated compared to control animals (statistical
analysis was not performed), only isolated replicates exceeded the
historical control range. Since most values for these parameters of
DNAmigrationwere below the laboratory's historical control range
the results were considered to fall within the normal level of
variation. No cytotoxicity, necrosis or apoptosis were observed in
cell suspensions.
Similarly, no statistically signiﬁcant increases in micronucleus
frequency were detected, indicating no evidence of genotoxicity in
the bonemarrow in this OECD compliant study. Although therewas
no bone marrow toxicity, exposure was veriﬁed based on liver ef-
fects as described above. The Panel concluded that 5-methyl-2-
thiophenecarboxaldehyde was not genotoxic in vivo following
oral intake up to the MTD of 700 mg/kg bw/day.
6.6.2. 3-Acetyl-2,5-dimethylthiophene
6.6.2.1. In vitro. The mutagenicity of 3-acetyl-2,5-
dimethylthiophene was tested in an Ames assay in Salmonella
typhimurium strains TA98, TA100, TA1535, TA1537 and TA102, both
in the absence and in the presence ofmetabolic activation (S-9 from
livers of rats induced with Aroclor 1254), at concentrations up to
5000 mg/plate using the plate incorporation methodology (Lillford,
2009). Toxicity was observed in all strains at 2000 and 5000 mg/
plate both in the absence and presence of S-9. In the presence of S-
9, clear, dose-related, statistically signiﬁcant (p < 0.01) and repro-
ducible increases in revertant numbers (up to 14-fold) were
observed in test strains TA98 and TA100, and to a much lower
extent (maximum 1.4-fold) in strain TA102 (but not in strains
TA1535 and TA1537). In contrast, no mutagenic activity was
observed in the absence of S-9 in any strain. These results indicate
that the mutagenic activity is related to metabolic products of 3-
acetyl-2,5-dimethylthiophene.
6.6.2.2. In vivo. The Muta™Mouse (lacZ/GalE) assay with an in vivo
micronucleus component is considered an appropriate follow-up
when positive results are obtained in the in vitro bacterial reverse
mutation assay (EFSA, 2011; OECD, 2011). Conclusions from the
study results are made by the laboratory performing the study and
evaluated by the Expert Panel.
The Muta™Mouse (lacZ/galE) assay detects the induction of
point mutations and small deletions in the lacZ gene, in any target
tissue where a substance is active. Brieﬂy, a l GT10 vector con-
taining a bacterial lacZ gene is incorporated in the genome of the
Muta™Mouse CD2-lacZ80/HazfBR strain and is therefore present in
every nucleated cell of the animal. Following treatment of
Muta™Mice with a test substance, cellular DNA is extracted from
tissues of interest and packaged into l bacteriophage which is then
used to transfect E. coli C lac- galE- Kanr (or galE- Ampr) cultures. The
number of plaques produced on non-selection (titer) plates in-
dicates the total number of viable bacteriophage units (transfected
E. coli). Mutations in the lacZ gene result in bacterial colonies
resistant to phenyl-galactose (P-Gal), a galactosidase substrate that
is toxic to galE bacterial strains expressing the non-mutated wildtype lacZ gene. Bacterial colonies of non-transfected E. coli are also
viable on plates containing P-Gal medium. However, only the
bacteria transfected with the bacteriophage carrying the mutated
lacZ gene result in bacterial lysis upon bacteriophage replication
and produce visible plaques, on a lawn of non-transfected (but
viable) bacteria. Mutant frequency is calculated as the ratio of the
number of bacteriophage containing mutated lacZ transgenes (i.e.,
plaques on positive selection plates) over the total number of viable
bacteriophage (i.e., visible plaques on titer plates) (Lambert et al.,
2005).
Therefore, theMuta™Mouse assaywas selected to further probe
the mutagenic potential of 3-acetyl-2,5-dimethylthiophene seen
in vitro. The liver and the duodenum were chosen as the most
appropriate tissues to address the potential for mutation, repre-
senting the site of most signiﬁcant metabolism and the site of ﬁrst
contact, respectively. Micronuclei were measured in peripheral
blood reticulocytes. The MTD of 350mg/kg bwwas determined in a
dose-range ﬁnding experiment (n¼ 3/sex/dose) following 7 days of
dosing by oral gavage, based on the toxicity displayed at higher
doses in this experiment.
Male Muta™Mouse CD2-lacZ80/HazfBR mice (6/dose) were
treated daily for 28 days by oral gavage with 3-acetyl-2,5-
dimethylthiophene at doses of 0, 120, 235 and 350 mg/kg bw/day
(the top dose was lowered to 300 mg/kg bw/day after 2 days of
dosing due to signs of distress). Animals were sacriﬁced three days
after the ﬁnal administration (day 31) and subjected to necropsy.
The functionality and validity of the mutation assays were ensured
by including a tissue-matched positive control DNA (from ethyl
nitrosourea-treated animals).
Treatment of Muta™Mice with 3-acetyl-2,5-dimethylthiophene
caused a dose-dependent increase in the mutation frequency of the
lacZ transgene in the liver, which was statistically signiﬁcant in the
middle and high dose groups and exceeded both concurrent and
historical control means. A small increase in lacZ mutation fre-
quency was also noted in the duodenum in the low and middle
dose groups, but it was not statistically signiﬁcant and remained
within the historical control range.
In contrast, no dose- or time-related increases in the frequency
of micronucleated peripheral blood reticulocytes were seen in
these animals. Small and statistically signiﬁcant but isolated in-
creases in micronuclei (at the high dose on day 4 and the middle
dose on day 31) were considered to bewithin the inherent variation
of the assay and without biological signiﬁcance. Considering the
positive mutagenic activity in the liver but not in the duodenum or
in the micronucleus assay, the mutagenic potential in vivo appears
to be related to a liver metabolite of 3-acetyl-2,5-
dimethylthiophene (Beevers, 2013). These results are consistent
with the pattern of mutagenicity seen in vitro.
Previously available genotoxicity data on structurally related
substances provide additional context for the interpretation of the
results of the genotoxicity studies for these two materials. A sum-
mary of genotoxicity studies on other thiophene compounds is
presented below:
6.6.3. Earlier genotoxicity studies with thiophene derivatives
6.6.3.1. Thiophenes negative for mutagenicity
6.6.3.1.1. Unsubstituted thiophene. Unsubstituted thiophenewas
negative for mutagenicity in the Ames assay with Salmonella
typhimurium strains TA100, TA1535, TA1537, TA97 and TA98 in
several studies, at concentrations up to 10,000 mg/plate with and
without metabolic activation from rat or hamster liver preparations
(Zeiger et al., 1987a,b; Shibuya, 2006; Aeschbacher et al., 1989).
Similarly, there was no mutagenic activity observed in a reverse
mutation assay in Escherichia coliWP2uvrA at concentrations up to
5000 mg/plate, with and without metabolic activation (Shibuya,
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Negative results were also reported in chromosomal aberrations
(CA) and polyploidy assays in Chinese hamster lung cells up to
840 mg/mL (Tanaka, 2006; Kusakabe et al., 2002).
6.6.3.1.2. Substituted thiophenes. No evidence of a mutagenic
response was previously reported in Salmonella typhimurium with
substituted thiophenes, including 2-methyl-, 3-methyl-, 2-acetyl-,
and 2,5-dimethyl-thiophenes, 5-methyl-2-
thiophenecarboxaldehyde, and 3-thiophene-carboxaldehyde, at
concentrations up to 100 mmol/plate with and without metabolic
activation (Lee et al., 1994; Aeschbacher et al., 1989). A summary of
these studies is shown in Table 7.
6.6.3.2. Thiophenes positive for mutagenicity. The number and type
of thiophene compounds that have shown mutagenic potential are
limited. Speciﬁcally, only polycyclic thiophenes (3 rings or more)
have been positive in Ames mutagenicity tests (Appendix A,
Table A-1). Of four 3-ring polycyclic aromatic sulfur heterocycles,
only naphtho[1,2-b]thiophene was mutagenic in the Salmonella
typhimurium TA100 strain and much less in the TA98 strain in an
Ames assay (Pelroy et al., 1983), whereas the naphtho[2,1-b]thio-
phene, differing only in the position of the sulfur atom, was not
mutagenic (Pelroy et al., 1983). Of thirteen 4-ring compounds,
seven were mutagenic and phenanthro[3,4-b]thiophene had the
highest activity, a compound of approximately the same mutagenic
potency in the Ames assay as benzo[a]pyrene (Pelroy et al., 1983). A
number of polycyclic aromatic sulfur heterocycles, including
dibenzothiophene, benzo[b]naphtho[1,2-d]thiophene, benzo[b]
naphtho[2,1-d]thiophene and benzo[b]naphtho[2,3-d]thiophene
have demonstrated either weak or no mutagenic activity using the
Salmonella typhimurium mutagenicity test (Pelroy et al., 1983;
McFall et al., 1984).
6.7. Conclusions for toxicity
Substitute thiophene ﬂavoring substances and structurally
related compounds have very low acute toxicity. In short term
studies with 5-methyl-2-thiophene carboxaldehyde, 3-acetyl-2,5-Table 7
Summary of in vitro and in vivo genotoxicity of structurally related thiophene compound
Compound Structure Assay
Thiophene Ames mutagenicity
S. typhimurium TA98, TA100
Escherichia coli WP2 uvrA re
Chromosomal aberrations
2-Methyl- Ames mutagenicity
S. typhimurium TA98, TA100
3-Methyl- Ames mutagenicity
S. typhimurium TA98, TA100
2-Acetyl- Ames mutagenicity
S. typhimurium TA98, TA100
2,5-Dimethyl- Ames mutagenicity
S. typhimurium TA98, TA100
3-Thiophene-carboxaldehyde Ames mutagenicity
S. typhimurium TA98, TA100dimethylthiophene, 5-ethyl-2-thiophene carboxaldehyde and
unsubstituted thiophene, no toxicity was observed at intake levels
below 100 mg/kg bw/day. In subchronic studies with 2-
thienyldisulﬁde, 2-pentylthiophene and 5-ethyl-2-thiophene car-
boxaldehyde few adverse effects were reported at high dose levels
and the NOAELs derived from these studies provide large margins
of safety when compared to estimated levels of exposure from use
as ﬂavoring substances (Table 4). The NOAELs for 2-
pentylthiophene, 2-thienyldisulﬁde and 5-ethyl-2-thiophene car-
boxaldehyde, are applicable to other alkyl-substituted, thiophenes
with sulfur in the side chain and acyl-substituted thiophene
ﬂavoring substances, respectively. In addition, the intake levels for
these thiophene substances are below the toxicological threshold
of concern (TTC) for their structural class. Therefore, there are
adequate data to support their safety under their speciﬁc intended
uses as ﬂavor ingredients added to food.
No evidence of genotoxicity has been found for simple
substituted thiophenes that are structural analogues of ﬂavoring
ingredients (Table 7). Alkyl-substituted thiophene ﬂavoring sub-
stances 2-pentylthiophene, 2-hexylthiophene, 3,4-
dimethylthiophene as well as 2-thienylmethanol are structurally
similar to methylthiophenes (2-, 3-, and 2,5-dimethyl-); the thio-
phene ﬂavoring substances with sulfur-containing side chains, 2-
thienyl mercaptan, 2-thienyldisulﬁde, 3-(methylthio)-methyl-
thiophene and 1-(2-thienyl)ethanethiol differ from simple alkyl
thiophenes due to the presence of the sulfur in the side chain. For
the purpose of genotoxicity assessment they are considered
structurally similar to simple alkylated thiophenes. 2-Acyl-
substituted thiophene ﬂavoring substances 1-(3-hydroxy-5-
methyl-2-thienyl)ethanone and 2-acetyl-5-methylthiophene are
structurally similar to 2-acetylthiophene and 5-methyl-2-
thiophenecarboxaldehyde. Methylthiophenes, 2-acetylthiophene
and 3-thiophene-carboxaldehyde (Table 7) and 5-methyl-2-
thiophenecarboxaldehyde (Table 6) are negative for genotoxicity.
The weak induction of micronuclei that was reported in vitro for 5-
methyl-2-thiophenecarboxaldehyde was not conﬁrmed when
tested in vivo. 3-Acyl substituted thiophene 3-acetyl-2,5-
dimethylthiophene is structurally similar to 3-thiophene-s.
Result Reference
, TA102, TA1535, TA1537, TA97
Negative Zeiger et al., 1987a,b
Shibuya 2006
Aeschbacher et al., 1989
Lee et al., 1994
verse mutation Negative Shibuya 2006
Negative Kusakabe et al., 2002
Tanaka 2006
, TA102
Negative Aeschbacher et al., 1989
Lee et al., 1994
, TA102
Negative Aeschbacher et al., 1989
Lee et al., 1994
Negative Lee et al., 1994
Negative Lee et al., 1994
Negative Lee et al., 1994
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is negative for genotoxicity, 3-acetyl-2,5-dimethylthiophene tested
positive for genotoxicity: it induced mutations in an Ames test in
three strains of Salmonella typhimurium in the presence of S-9
activation and these in vitro results were also conﬁrmed in the
Muta™Mouse assay in vivo. However, 3-acetyl-2,5-
dimethylthiophene was negative for mutagenicity in the absence
of metabolic activation in vitro and in the in vivomicronucleus assay
in bone marrow of male rats when dosed up to the MTD. Overall,
the data indicate that its genotoxicity is related to an unknown
active metabolite generated in the liver. There is no concern about
the genotoxic potential of the thiophene ﬂavoring substances
evaluated in this report, except for 3-acetyl-2,5-
dimethylthiophene. The only other thiophenes that have been re-
ported positive for genotoxicity are polycyclic thiophene de-
rivatives, compounds with very different chemical reactivities than
the thiophenes used as ﬂavoring ingredients (Table A-1).
7. Discussion
Thiophene ﬂavoring substances are used at very low levels in
food, resulting in low estimated daily intakes. In addition, several
thiophene compounds occur naturally in foods. The intake of
thiophene substances from natural sources far exceeds the intake
from their use as added ﬂavors. Toxicity studies conducted with
alkyl, thienyl-, and acyl-substituted thiophenes are representative
of the group of thiophene ﬂavoring substances. Together they
provide large margins of safety relative to the low estimated in-
takes from use as ﬂavors added to food.
Genotoxicity data on several substituted thiophenes also sup-
port lack of genotoxic potential for the group of thiophene ﬂavoring
substances. However, concern for genotoxicity cannot be excluded
for one member of this group, 3-acetyl-2,5-dimethylthiophene
which displayed mutagenic activity in vitro (in the presence of
metabolic activation) and in vivo (Tables 5e7). While 5-methyl-2-
thiophenecarboxaldehyde showed some equivocal evidence of
genotoxic potential in the micronucleus test in vitro, this was not
conﬁrmed in a follow-up in vivo micronucleus test suggesting lack
of biological relevance of the in vitro test. The genotoxic activity of
3-acetyl-2,5-dimethylthiophene stands in contrast to the collective
evidence for the remaining thiophene substances in the group and
is attributed to the formation of reactive metabolites. The positive
mutagenic response of 3-acetyl-2,5-dimethylthiophene was
limited to conditions including metabolic activation in vitro in the
absence of GSH (Ames test þ S-9) or in the liver of the Muta™-
Mouse, the tissue of maximum metabolic activity. Indeed, the du-
odenum, site of ﬁrst contact, did not display a signiﬁcant mutagenic
response to orally administered 3-acetyl-2,5-dimethylthiophene.
Ultimately, a carcinogenicity study in rodents would be the most
direct way to assess the biological signiﬁcance of the genotoxicity
evidence reported for 3-acetyl-2,5-dimethylthiophene.
A closer look at the metabolic pathways involved in the detox-
ication of thiophene compounds provides possible reasons for the
divergent behavior of the compound in question. It is consistent
with the effective formation of a reactive metabolite coupled with
inefﬁcient GSH conjugation and elimination.
Ring epoxidation and S-oxidation are the known primary
pathways for biotransformation of thiophene derivatives, and the
relative contribution of each pathway is a function of the thiophene
substructure. GSH conjugation of the reactive intermediate seems
to be a key element in inhibiting covalent binding by acting as a
sink for the reactive metabolites, as demonstrated by Dansette
et al., (1990, 2005) and Valadon et al., (1996). When comparing
the metabolic fate of thiophene derivatives, a pattern emerges that
involves the type (Mansuy et al., 1991), position (Dansette et al.,1990; Valadon et al., 1996; Rademacher et al., 2012) and number
of substitution groups. The reactivity increases with a) the presence
of a carbonyl group compared to simple aliphatic side chains
(Mansuy et al., 1991); b) substitution in position 3 compared to
position 2 of the ring (Dansette et al., 1990; Valadon et al., 1996;
Rademacher et al., 2012); and c) more extensive substitution
(higher number of side groups). The S-oxide pathway leads to more
reactive intermediates compared to the ring epoxidation pathway.
The presence and position of a carbonyl group at C3 renders the S-
oxide more electrophilic, as indicated by the ratios of stable-to-
reactive metabolites of 0.25 and 2, respectively, for 3-
aroylthiophene (TAI) and 2-aroylthiophene (TA), following micro-
somal incubation (Dansette et al., 1990). Furthermore, the S-
oxidation is favored in 3-acylthiophenes compared to the 2-
acylthiophenes (Rademacher et al., 2012) and position 2 is the
most vulnerable to nucleophilic attack (Mansuy et al., 1991;
Dansette et al., 1992; Valadon et al., 1996). A comparison of struc-
tural features and metabolic outcomes is summarized in Table 8.
Based on these insights from model thiophene structures, it is
expected that in the case of 3-acetyl-2,5-dimethylthiophene, the S-
oxidation is favored compared to the ring oxidation, due to the
position of the acyl group (3- vs 2-), and results in a more reactive
intermediate (S-oxide intermediates are more reactive compared to
ring epoxide intermediates). The metabolic pathway leading to a
ring epoxide is less likely to occur in 3-acetyl-2,5-
dimethylthiophene, not only because it is 5 times less favored in
3-acyl compared to 2-acyl thiophenes (Dansette et al., 1990) but
also because this molecule bears two additional substitution
groups compared to the model structure TAI. The dimerization
product seen with 2-phenylthiophene would also be less likely for
3-acetyl-2,5-dimethylthiophene for similar reasons. Thus,
following CYP activation in vivo or in vitro, a sulfoxide appears to be
the likely reactive metabolite for 3-acetyl-2,5-dimethylthiophene
(Fig. 5). In addition, GSH conjugation on the S-oxide intermediate
of 3-acetyl-2,5-dimethylthiophene, which normally occurs on 2- or
5- positions of 3-substituted model thiophenes, may be less efﬁ-
cient due to the presence of methyl groups on both ring positions 2
and 5. Therefore, detoxication of the reactive intermediate to less
reactive and stable products may be less effective for this structure
compared to the other substituted thiophenes in the group. How-
ever, although GSH binding may be inefﬁcient it should not be
presumed to be absent. The S-oxide intermediate is an electrophilic
molecule and reactive toward nucleophiles, including but not
limited to GSH. In the presence of multiple nucleophilic partners,
binding can be subject to competition. Unless the electrophile is
promptly stabilized by GSH to a less reactive product, the proba-
bility of interaction with other macromolecules increases along
with the probability of resulting effects.
With regards to 5-methyl-2-thiophenecarboxaldehyde, the
presence of the carbonyl group may explain the positive, albeit
weak, genotoxic activity in vitro compared to absence of genotox-
icity of unsubstituted thiophene, or mono- and bi-substituted alkyl
thiophenes. The location of the carbonyl group in 5-methyl-2-
thiophenecarboxaldehyde on position 2 instead of position 3 may
explain the rather weak genotoxic activity observed, presumably
due to lower reactivity (low yield of S-oxide intermediates) as
suggested by the difference in reactivity between the structural
analogues TA and TAI (Dansette et al., 1990). Furthermore, conju-
gation of reactive metabolites with GSH and conversion of reactive
metabolites to a carboxylic acid may explain the absence of geno-
toxicity of 5-methyl-2-thiophenecarboxaldehyde in vivo. (Table 8).
Interestingly, two other thiophene ﬂavoring ingredients, 2-
acetyl-5-methylthiophene and 1-(3-hydroxy-5-methyl-2-thienyl)
ethanone, share similar features with 3-acetyl-2,5-
dimethylthiophene, such as the presence of the acyl group and
Table 8
Structural features and metabolic fate of model thiophenes and selected thiophene ﬂavoring substances.
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both of these compounds are less likely to be as reactive and more
likely to be efﬁciently conjugated for the following reasons: a) both
structures have the acyl substituent on position 2 of the ring
(compared to position 3), which favors ring oxidation rather than S-
oxidation reactions; b) the ﬁrst structure has only one other sub-
stituent, which presents less hindrance for GSH conjugation
following ring oxidation; and c) the second structure has a hydroxy
substituent on position 3 which is readily available for conjugation
reactions.
The relative structural features and the expected metabolic fate
of thiophene ﬂavoring ingredients are presented in Table 8.While the mechanism leading to the genotoxicity of 3-acetyl-
2,5-dimethylthiophene is not currently known, the available evi-
dence provides reasonable support for its divergent behavior
relative to the other substituted thiophenes in this group of
ﬂavoring substances (Table 8). Among all the substituted thio-
phenes studied to date, most are negative for genotoxicity (Table 7).
The only other compounds with genotoxic potential are the poly-
cyclic thiophenes with extended fused ring structures, such as
phenanthrol[3,4-b]thiophene (Table A-1) (Pelroy et al., 1983). The
genotoxicity of those structures are likely related to the other ring
substructure rather than to a reactive thiophene intermediate. The
ﬂavoring substances reviewed in this report do not possess fused
S.M. Cohen et al. / Food and Chemical Toxicology 99 (2017) 40e5956ring structures and are not considered by the Panel as structurally
related to the polycyclic substituted class of thiophenes.
Taken together, the available data on thiophenemetabolism and
the pattern of mutagenic responses among thiophene compounds
indicate that 3-acetyl-2,5-dimethylthiophene presents an atypical
case among the group of thiophene ﬂavoring substances, where
metabolic transformation favors the formation of a reactive product
but not its detoxication at high exposure doses and/or when GSH
stores are depleted. Based on the available evidence from a battery
of published genotoxicity studies on the thiophene ﬂavor group,
this behavior does not present concern for genotoxic potential for
the remaining substances in this group.8. Conclusion
The group of thiophene-based ﬂavoring substances discussed
here was previously determined to be generally recognized as safe
(GRAS) under conditions of intended use as ﬂavor ingredients by
the FEMA Expert Panel (Hall and Oser, 1965, 1970; Oser and Hall,
1972; Oser and Ford, 1978; Smith et al., 2005b, 2009; Waddell
et al., 2007). In 1978, the Panel evaluated the available data and
afﬁrmed the GRAS status of all previously GRAS ﬂavor ingredients
(GRASa). In 1993, the Panel initiated a comprehensive program to
re-evaluate the status of all FEMA GRAS ﬂavor ingredients con-
current with a systematic revision of the FEMA Scientiﬁc Literature
Reviews (available from the National Technical Information Service,
NTIS) and the Panel reafﬁrmed the status of 4 members of this
group in 2001 with GRASr status. In the interim, new data have
become available for two substances, 5-methyl-2-
thiophenecarboxaldehyde and 3-acetyl-2,5-dimethylthiophene, in
recent genotoxicity studies conducted according to OECD guide-
lines. The new studies did not present any concern for genotoxicity
for 5-methyl-2-thiophenecarboxaldehyde. In contrast, results of
in vitro and in vivo studies for 3-acetyl-2,5-dimethylthiophene raise
a concern for genotoxicity. The genotoxicity of 3-acetyl-2,5-
dimethylthiophene in the assays is unexplained mechanistically,
however, based upon knowledge of the metabolic fate of thio-
phenes, it appears to be related to speciﬁc metabolic differences as
a result of structural features unique to this substance compared to
the remaining thiophene substances in the group.
The FEMA GRAS status of 3-acetyl-2,5-dimethylthiophene
(formerly FEMA No 3527) under conditions of intended use as a
ﬂavor ingredient was reviewed by the Panel. Based on the available
scientiﬁc evidence related to safety, the Panel concluded that
additional data, including more detailed exposure information,
comparative metabolism studies, and more comprehensive toxicity
data including an in-depth evaluation of the mechanism of action
for potential adverse effects are required. Until such data areTable A-1
Summary of in vitro genotoxicity of polycyclic thiophene compounds.
Compound Structure Assay
Naphthol[1,2-b]thiophene Ames mut
Naphthol[2,1-b]thiophene Ames mut
Naphthol[2,3-b]thiophene Ames mutavailable for review, the ﬂavor ingredient 3-acetyl-2,5-
dimethylthiophene has been removed from the GRAS list. The
Panel also reviewed data for related alkyl-substituted thiophene
substances and conﬁrmed that no change in the GRAS status of
their uses was warranted.
Overall there is sufﬁcient available genetic toxicity testing data
to indicate that, with the exception of the ﬂavoring substance 3-
acetyl-2,5-dimethylthiophene, the group of the 11 remaining
thiophene-based ﬂavoring substances does not present any
concern with respect to genotoxicity. Therefore, the Expert Panel
ﬁnds that the remaining 11 thiophene ﬂavoring substances are re-
afﬁrmed as GRAS based on their rapid absorption, metabolic con-
version, and excretion in humans and animals; their low levels of
use as ﬂavors in food; the wide margins of safety between the
conservative estimates of intake and the experimentally deter-
mined NOAEL or NOELs derived from repeat dose subchronic oral
toxicity studies in rodents as well as a lack of signiﬁcant, biologi-
cally relevant genotoxic potential. The consistency of the results
obtained from appropriately conducted in vivo subchronic toxicity
studies in rodent models at high doses support the conclusion that
consumption of these thiophene substances under intended use
conditions as ﬂavors in food is not a concern for human health.
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Appendix AResult Reference
agenicity Positive a, b, c, d Pelroy et al., 1983
agenicity Negative Pelroy et al., 1983
agenicity Negative
Weakly pos.a, c, d Weakly pos.e, f, d
Pelroy et al., 1983
Table A-1 (continued )
Compound Structure Assay Result Reference
Dibenzothiophene Ames mutagenicity Negative
Weakly pos.a, g, d
Weakly pos.b, f, c
Pelroy et al., 1983
McFall et al., 1984
Benzo[b]naphtho[1,2-d]thiophene Ames mutagenicity Negative Pelroy et al., 1983
McFall et al., 1984
Benzo[b]naphtho[2,1-d]thiophene Ames mutagenicity Weakly pos.a, b, d
Weakly pos.e, f, d
Weakly pos.b, f, c
Pelroy et al., 1983
McFall et al., 1984
Benzo[b]naphtho[2,3-d]thiophene Ames mutagenicity Negative Pelroy et al., 1983
McFall et al., 1984
Phenanthrol[3,4-b]thiophene Ames mutagenicity Positive a, b, c, d Pelroy et al., 1983
Phenanthrol[4,3-b]thiophene Ames mutagenicity Negative Pelroy et al., 1983
Phenanthrol[2,1-b]thiophene Ames mutagenicity Weakly pos.d, e, a, f Pelroy et al., 1983
Phenanthrol[1,2-b]thiophene Ames mutagenicity Weakly pos.e, f, d Pelroy et al., 1983
Phenanthrol[2,3-b]thiophene Ames mutagenicity Weakly pos.e, f, d Pelroy et al., 1983
Phenanthrol[3,2-b]thiophene Ames mutagenicity Weakly pos.e, f, d
Weakly pos.b, f, c
Pelroy et al., 1983
Anthra[1,2-b]thiophene Ames mutagenicity Positive a, b, c, d
Positive b, f, c
Positive e, f, d
Pelroy et al., 1983
Anthra[2,1-b]thiophene Ames mutagenicity Positive a, b, c, d
Positive b, f, c
Positive e, f, d
Pelroy et al., 1983
Anthra[2,3-b]thiophene Ames mutagenicity Positive a, b, c, d Pelroy et al., 1983
a Plate incorporation method.
b With S-9.
c Strain TA98.
d Strain TA100.
e Without S-9.
f Pre-incubation method.
g With and without S-9.
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